Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Notes Payables (2022 - 2026)

HeartSciences' Notes Payables history spans 5 years, with the latest figure at $3.1 million for Q1 2026.

  • For Q1 2026, Notes Payables rose 22.7% year-over-year to $3.1 million; the TTM value through Jan 2026 reached $3.1 million, up 22.7%, while the annual FY2025 figure was $2.6 million, 410.23% up from the prior year.
  • Notes Payables reached $3.1 million in Q1 2026 per HSCS's latest filing, up from $500000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $3.1 million in Q1 2026 to a low of $130000.0 in Q3 2022.
  • Average Notes Payables over 5 years is $1.3 million, with a median of $1.1 million recorded in 2022.
  • The largest YoY upside for Notes Payables was 410.23% in 2025 against a maximum downside of 78.87% in 2025.
  • A 5-year view of Notes Payables shows it stood at $1.1 million in 2022, then grew by 25.41% to $1.4 million in 2023, then skyrocketed by 67.01% to $2.4 million in 2024, then tumbled by 78.87% to $500000.0 in 2025, then skyrocketed by 519.94% to $3.1 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Notes Payables are $3.1 million (Q1 2026), $500000.0 (Q4 2025), and $1.5 million (Q3 2025).